Terms: = Prostate cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Treatment
584 results:
1. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
2. Other-cause mortality in incidental prostate cancer.
Di Bello F; Baudo A; de Angelis M; Jannello LMI; Siech C; Tian Z; Goyal JA; Collà Ruvolo C; Califano G; La Rocca R; Morra S; Acquati P; Saad F; Shariat SF; Carmignani L; de Cobelli O; Briganti A; Chun FKH; Longo N; Karakiewicz PI
Prostate; 2024 Jun; 84(8):731-737. PubMed ID: 38506561
[TBL] [Abstract] [Full Text] [Related]
3. prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO).
Koerber SA; Höcht S; Aebersold D; Albrecht C; Boehmer D; Ganswindt U; Schmidt-Hegemann NS; Hölscher T; Mueller AC; Niehoff P; Peeken JC; Pinkawa M; Polat B; Spohn SKB; Wolf F; Zamboglou C; Zips D; Wiegel T
Strahlenther Onkol; 2024 Mar; 200(3):181-187. PubMed ID: 38273135
[TBL] [Abstract] [Full Text] [Related]
4. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
[TBL] [Abstract] [Full Text] [Related]
5. Variation in patterns of second primary malignancies across U.S. race and ethnicity groups: a Surveillance, Epidemiology, and End Results (SEER) analysis.
McGuire V; Lichtensztajn DY; Tao L; Yang J; Clarke CA; Wu AH; Wilkens L; Glaser SL; Park SL; Cheng I
Cancer Causes Control; 2024 May; 35(5):799-815. PubMed ID: 38206498
[TBL] [Abstract] [Full Text] [Related]
6. Evaluating Policies of Expanding Versus Restricting First-Line treatment Choices: A Cost-Effectiveness Analysis Framework.
Jiao B; Carlson JJ; Garrison LP; Basu A
Value Health; 2024 Apr; 27(4):433-440. PubMed ID: 38191022
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic significance of surgery and radiotherapy in elderly patients with localized prostate cancer: establishing and time-based external validation a nomogram from SEER-based study.
Zhanghuang C; Zhu J; Li Y; Wang J; Ma J; Li L; Yao Z; Ji F; Wu C; Tang H; Xie Y; Yan B; Yang Z
BMC Urol; 2024 Jan; 24(1):12. PubMed ID: 38184526
[TBL] [Abstract] [Full Text] [Related]
8. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
9. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
10. prostate Volume is A Predictor of Gleason Score Upgrading after Radical prostatectomy in Low-Risk prostate cancer: A Systematic Review and Meta-analysis.
Zou Q; Cao J; Chen Z; Wang S; Gu C; Li S; Xiang S
Urol J; 2024 Feb; 21(1):20-28. PubMed ID: 38087971
[TBL] [Abstract] [Full Text] [Related]
11. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients.
Samaratunga H; Egevad L; Yaxley J; Perry-Keene J; Le Fevre I; Kench J; Matsika A; Bostwick D; Iczkowski K; Delahunt B
Pathology; 2024 Feb; 56(1):33-38. PubMed ID: 38071161
[TBL] [Abstract] [Full Text] [Related]
12. A radiomics based method for prediction of prostate cancer Gleason score using enlarged region of interest.
Zhuang H; Chatterjee A; Fan X; Qi S; Qian W; He D
BMC Med Imaging; 2023 Dec; 23(1):205. PubMed ID: 38066434
[TBL] [Abstract] [Full Text] [Related]
13. Can systemic immune-inflammation index and hematologic parameters aid in decision-making for active surveillance or curative treatment in low-risk prostate cancer?
Baylan B; Ulusoy K; Ekenci B; Kartal IG
Asian J Surg; 2024 Mar; 47(3):1360-1365. PubMed ID: 38065745
[TBL] [Abstract] [Full Text] [Related]
14. Review of the Developing Landscape of prostate Biopsy and Its Roles in prostate cancer Diagnosis and treatment.
Okubo Y; Sato S; Terao H; Yamamoto Y; Suzuki A; Hasegawa C; Yoshioka E; Ono K; Washimi K; Yokose T; Nakaigawa N; Kishida T; Miyagi Y
Arch Esp Urol; 2023 Nov; 76(9):633-642. PubMed ID: 38053418
[TBL] [Abstract] [Full Text] [Related]
15. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
16. Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients.
Zheng T; Sun H; Tang Y; Bi K; Zeng Y; Wang J; Yan L
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18029-18037. PubMed ID: 37979056
[TBL] [Abstract] [Full Text] [Related]
17. Psychometric validation of the Spanish version of the Expanded prostate cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract] [Full Text] [Related]
18. Systemic Inflammatory Index: A Novel Biomarker for Predicting the Progression in Active Surveillance in Patients with prostate cancer.
Ozcan L; Omur M; Polat EC; Baran C; Boylu A; Otunctemur A
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1278-1282. PubMed ID: 37926881
[TBL] [Abstract] [Full Text] [Related]
19. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract] [Full Text] [Related]
20. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
[Next]
